Effects of erythromycin on γ-glutamyl cysteine synthetase and interleukin-1β in hyperoxia-exposed lung tissue of premature newborn rats

Cai, Cheng; Qiu, Gang; Gong, Xiaohui; Chen, Yihuan; Zhao, Huan-hu

doi:10.1016/j.jped.2014.01.013

Cited by 13 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Morikawa et al ( 36 ) assessed the effect of EM in patients with diffuse panbronchiolitis and observed an increase in superoxide dismutase activity. Similarly, Cai et al ( 31 ) observed an increase in glutathione activity in rats treated with EM in a model of hyperoxia. These findings were accompanied by suppression of inflammatory cytokines and attenuation of the clinical features.…”

Section: Resultsmentioning

confidence: 75%

See 1 more Smart Citation

Erythromycin: an alternative for the management of oral mucositis?

Teixeira¹,

Louzeiro²,

Figueiredo³

et al. 2022

Med Oral

View full text Add to dashboard Cite

Background Oral mucositis (OM) is an important acute adverse effect of anticancer therapy. This condition presents high morbidity and may lead to the suspension of anticancer therapy. Material and Methods We reviewed the literature on the pathobiology of OM and the properties of erythromycin (EM), to consider the possibility of its use for the prevention and treatment of OM. We searched the PubMed, Scopus and Web of Science databases and selected complete articles published in English or Spanish that met the inclusion criteria. The search terms “erythromycin”, “inflammation”, “immunomodulation” and “oral mucositis” were used. Results The control of free radicals, transcription factors and pro-inflammatory cytokines has been considered as the key to the management of OM. EM has the ability to modulate oxidative stress, acts on the transcriptional system and inhibits the production of several cytokines that have been directly implicated in OM pathobiology. Conclusions The present review suggests that EM could be effective in the treatment of OM. Experimental studies investigating the use of EM in OM should be encouraged. Key words: Oral mucositis, erythromycin, inflammation, immunomodulation, oxidative stress.

show abstract

Section: Resultsmentioning

confidence: 75%

“…The immunomodulatory activity of EM has been extensively investigated in respiratory disorders, characterized by exacerbated inflammatory response and deleterious effects on tissues. Table 2 presents pre-clinical studies showing the effects of EM on cell function, inflammatory cytokines and oxidative stress ( 7 , 21 - 31 ).…”

Section: Resultsmentioning

confidence: 99%

Erythromycin: an alternative for the management of oral mucositis?

Teixeira¹,

Louzeiro²,

Figueiredo³

et al. 2022

Med Oral

View full text Add to dashboard Cite

show abstract

“…Treatment with MPP increased cellular reduced GSH level and inhibited As(III)-induced ROS production (Figures 5(a) and 5(c) ). The upregulation of reduced GSH by MPP was consistent with its action on the increased protein level of GCLM, a key enzyme for GSH synthesis [ 48 ]. Accordingly, downregulation of ROS production by MPP inhibited As(III)-induced death and cell apoptosis (Figures 5(b) and 5(d) ).…”

Section: Discussionmentioning

confidence: 81%

Ingredients from Litsea garrettii as Potential Preventive Agents against Oxidative Insult and Inflammatory Response

Sun

et al. 2018

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Oxidative stress and inflammation undoubtedly contribute to the pathogenesis of many human diseases. The nuclear transcription factor erythroid 2-related factor (Nrf2) and the nuclear factor κB (NF-κB) play central roles in regulation of oxidative stress and inflammation and thus are targets for developing agents against oxidative stress- and inflammation-related diseases. Our previous study indicated that the EtOH extract of Litsea garrettii protected human bronchial epithelial cells against oxidative insult via the activation of Nrf2. In the present study, a systemic phytochemical investigation of L. garrettii led to the isolation of twenty-one chemical ingredients, which were further evaluated for their inhibitions on oxidative stress and inflammation using NAD(P)H:quinone reductase (QR) assay and nitric oxide (NO) production assay. Of these ingredients, 3-methoxy-5-pentyl-phenol (MPP, 5) was identified as an Nrf2 activator and an NF-κB inhibitor. Further studies demonstrated the following: (i) MPP upregulated the protein levels of Nrf2, NAD(P)H:quinone oxidoreductase 1 (NQO1), and glutamate-cysteine ligase regulatory subunit (GCLM); enhanced the nuclear translocation and stabilization of Nrf2; and inhibited arsenic [As(III)]-induced oxidative insult in normal human lung epithelial Beas-2B cells. And (ii) MPP suppressed the nuclear translocation of NF-κB p65 subunit; inhibited the lipopolysaccharide- (LPS-) stimulated increases of NF-κB p65 subunit, COX-2, iNOS, TNF-α, and IL-1β; and blocked the LPS-induced biodegrade of IκB-α in RAW 264.7 murine macrophages. Taken together, MPP displayed potential preventive effects against inflammation- and oxidative stress-related diseases.

show abstract

“…RNA concentration can be quantified by means of a NanoDrop ND-2000 spectrophotometer (NanoDrop, Wilmington, DE). Next, reverse transcription (RT) reactions and real-time PCR were carried out in accordance with the methods described previously [12]. The expression coefficient of miRNA-574-3p and ADM relative to β-actin was calculated using the 2 − C t method.…”

Section: Total Rna Isolation and Real-time Q-pcr Verificationmentioning

confidence: 99%

Adrenomedullin regulated by miRNA-574-3p protects premature infants with bronchopulmonary dysplasia

Gong

Qiu

et al. 2020

Bioscience Reports

Self Cite

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease (CLD) in premature infants. The present study was designed to elucidate the regulation of miRNA-547-3p on adrenomedullin (ADM) during the pathogenesis of BPD. We used Agilent Human 4x44K Gene Expression Microarrays v2 and miRCURY LNA™ microRNA Array to identify the differently expressed miRNA and its potential target genes, and certified them again by luciferase reporter gene analysis. We only retained target genes that met the following two conditions: first, coexisting in two databases, and second, expressing differences, and then identifying target genes by luciferase reporter gene analysis. Thus, we selected miRNA-574-3p and its target gene ADM for further research. We used real-time q-PCR to determine the expression of miRNA-574-3p and its target gene ADM in premature infants with BPD. We used microarray expression to analyze BPD samples and non-BPD samples and found that there were 516 differently expressed probes between them. The 516 differently expressed probes included 408 up-regulated probes and 108 down-regulated probes. The blood samples of BPD infants were detected by real-time q-PCR and found that the expression of miRNA-574-3p was decreased, while the expression of ADM was significantly increased. Luciferase reporter gene analysis showed that hsa-miR-574-3p can regulate the expression of luciferase with ADM 3′UTR, and decrease it by 61.84%. It has been reported in the literature that ADM can protect the premature infants with BPD. The target gene ADM of miRNA-574-3p may contribute to the prevention and treatment of BPD.

show abstract

Effects of erythromycin on γ-glutamyl cysteine synthetase and interleukin-1β in hyperoxia-exposed lung tissue of premature newborn rats

Cited by 13 publications

References 15 publications

Erythromycin: an alternative for the management of oral mucositis?

Erythromycin: an alternative for the management of oral mucositis?

Ingredients from Litsea garrettii as Potential Preventive Agents against Oxidative Insult and Inflammatory Response

Adrenomedullin regulated by miRNA-574-3p protects premature infants with bronchopulmonary dysplasia

Contact Info

Product

Resources

About